In WT and obese animals, AOD9604 reduces fat mass, increases 3-AR expression, enhances lipolysis, and stimulates energy expenditure and fat oxidation
Not in people who are not deficient
Mechanism difference Semaglutide (GLP-1 agonist): appetite regulation, satiety, improved glycemic control (New England Journal of Medicine) Tirzepatide (GLP-1/GIP agonist): broader incretin effects, robust appetite/weight effects (New England Journal of Medicine) AOD-9604: targeted fat-metabolism signaling
Each component of our stacks is individually verified by two independent analyses before co-formulation: HPLC chromatography (purity 98%) and LC-MS mass spectrometry (confirmation of molecular mass)
The breadth of proposed effects in the animal literature is unusual for a compound with such a clean mechanistic profile
Is compounded semaglutide the same as Ozempic or Wegovy